P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Ítems similars

• P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
  per: Fadi Haddad, et al.
  Publicat: (2023-08-01)
• P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
  per: Nicholas Short, et al.
  Publicat: (2023-08-01)
• P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB
  per: W. Macaron, et al.
  Publicat: (2022-06-01)
• Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia
  per: Daniel Nguyen, et al.
  Publicat: (2026-03-01)
• P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
  per: N. Short, et al.
  Publicat: (2022-06-01)